These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19049377)

  • 1. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.
    Heise T; Eckers U; Kanc K; Nielsen JN; Nosek L
    Diabetes Technol Ther; 2008 Dec; 10(6):479-85. PubMed ID: 19049377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30).
    Bott S; Tusek C; Heinemann L; Friberg HH; Heise T
    Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):545-50. PubMed ID: 16235159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus.
    McSorley PT; Bell PM; Jacobsen LV; Kristensen A; Lindholm A
    Clin Ther; 2002 Apr; 24(4):530-9. PubMed ID: 12017398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy.
    Heise T; Heinemann L; Hövelmann U; Brauns B; Nosek L; Haahr HL; Olsen KJ
    Diabetes Care; 2009 Aug; 32(8):1431-3. PubMed ID: 19487640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.
    Heise T; Zijlstra E; Nosek L; Rikte T; Haahr H
    Diabetes Obes Metab; 2017 Feb; 19(2):208-215. PubMed ID: 27709762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
    Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
    Haahr H; Sasaki T; Bardtrum L; Ikushima I
    J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes.
    Luzio S; Dunseath G; Peter R; Pauvaday V; Owens DR
    Diabetologia; 2006 Jun; 49(6):1163-8. PubMed ID: 16596358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes.
    Hermansen K; Vaaler S; Madsbad S; Dalgaard M; Zander M; Begtrup K; Soendergaard K
    Metabolism; 2002 Jul; 51(7):896-900. PubMed ID: 12077738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
    Heise T; Hövelmann U; Zijlstra E; Stender-Petersen K; Jacobsen JB; Haahr H
    Drugs Aging; 2017 Jan; 34(1):29-38. PubMed ID: 27873152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
    Heise T; Nosek L; Klein O; Coester H; Svendsen AL; Haahr H
    Diabetes Obes Metab; 2015 Jul; 17(7):659-64. PubMed ID: 25772444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes.
    Ejskjaer N; Rasmussen M; Kamp N; Lindholm A; Christiansen JS
    Diabetes Obes Metab; 2003 Nov; 5(6):438-45. PubMed ID: 14617230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
    Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
    Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
    Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
    Niskanen L; Leiter LA; Franek E; Weng J; Damci T; Muñoz-Torres M; Donnet JP; Endahl L; Skjøth TV; Vaag A
    Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus.
    Haahr H; Pieber TR; Mathieu C; Gondolf T; Shiramoto M; Erichsen L; Heise T
    Clin Pharmacokinet; 2019 May; 58(5):639-649. PubMed ID: 30402720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
    Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.